The complete remission rate (CRR) of CD19-targeted CAR-T (CAR-T-19) cells in the treatment of B cell acute lymphocytic leukemia (B-ALL) could be more than 90% [2, 3]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.